TYO:4594

BrightPath Biotherapeutics Co.,Ltd. Stock Insider Trading

Tokyo Stock Exchange > Healthcare > Biotechnology

Open Broker Account

JP¥64.00

+3.00 (+4.92%)

At Close: Jun 14, 2024

There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:

Sorry! Image not available at this moment

About BrightPath Biotherapeutics Co.,Ltd.

BrightPath Biotherapeutics Co., Ltd. develops cancer immunotherapy drugs. The company is developing GRN-1201 that is in Phase II clinical study for the treatment of non-small cell lung cancer, as well as in Phase I clinical study to treat melanoma. It also develops BP1101, a neoantigen vaccine; BP1209, a platform of personalized neoantigen cancer vaccines; and BP1401, an agonist for toll-like receptor 9. In addition, the company offers induced pl... 4594.T Profile

Golden Star

Ticker	Date	Change	Price
LIN	Jun 12	0.640%	$434.17
BNDX	Jun 12	0.637%	$48.64
MAIN	Jun 12	0.673%	$49.01
EQR	Jun 11	1.77%	$65.55
RPM	Jun 11	0.92%	$110.28
FR	Jun 11	1.52%	$46.78
CAH	Jun 11	1.20%	$99.01
ESI	Jun 11	11.50%	$23.73
FTGC	Jun 11	0.374%	$24.09
FTSM	Jun 11	0.0838%	$59.68

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by

Sign In

BrightPath Biotherapeutics Co.,Ltd. Stock Insider Trading

About BrightPath Biotherapeutics Co.,Ltd.

Golden Star

Top Fintech Company